What they're saying: According to the lawsuit, one of the plaintiffs switched from Zepbound to Wegovy in August after exhausting all appeals to Caremark, then "experienced a number of side effects, including the return of his Gastroesophageal Reflux Disease, stomach pain, hunger, and, most notably, weight gain." "Because of their different methods of action, different clinical outcomes, and different side effects for individual patients, Zepbound and Wegovy are not clinically interchangeable," the lawsuit states
Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes
19 GLP-2 also enhances intestinal barrier function, increases glucose transport, and boosts mesenteric blood flow
GLP-3 Reta is investigated for similar indications with particular interest in severe obesity where maximum metabolic effect is studied